Get the Stockscreener App
59.94
0.61%
-0.37
After Hours:
59.94
Biomarin Pharmaceutical Inc stock is traded at $59.94, with a volume of 4.42M.
It is down -0.61% in the last 24 hours and up +3.86% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
See More
Previous Close:
$60.31
Open:
$58.39
24h Volume:
4.42M
Relative Volume:
1.68
Market Cap:
$11.52B
Revenue:
$2.95B
Net Income/Loss:
$523.88M
P/E Ratio:
22.28
EPS:
2.69
Net Cash Flow:
$620.18M
1W Performance:
+4.88%
1M Performance:
+3.86%
6M Performance:
+5.42%
1Y Performance:
-8.99%
1-Day Range:
$57.84
$61.48
1-Week Range:
$57.26
$61.48
52-Week Range:
$50.76
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
59.94 | 11.59B | 2.95B | 523.88M | 620.18M | 2.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-20-26 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Nov-06-25 | Downgrade | Stifel | Buy → Hold |
| Sep-08-25 | Initiated | H.C. Wainwright | Neutral |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
Looking To Compete With BioMarin, Ascendis Continues Its Growth Story - Citeline News & Insights
BioMarin Raises $850 Million Notes for Amicus Acquisition - TipRanks
BioMarin Signs Indenture For Senior Notes With U.S. Bank Trust Company - TradingView
BioMarin finances Amicus acquisition with $850M notes and new loans - Stock Titan
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Benzinga
BioMarin Pharmaceutical, Amicus Therapeutics deal gets early termination from US FTC - MLex
BridgeBio scores with dwarfism drug, setting up showdown with BioMarin, Ascendis - BioPharma Dive
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release - Finviz
Baird maintains BioMarin stock rating amid competitor’s positive trial data By Investing.com - Investing.com India
Baird maintains BioMarin stock rating amid competitor’s positive trial data - Investing.com
BioMarin, Ascendis stocks fall after BridgeBio’s positive achondroplasia data By Investing.com - Investing.com UK
BridgeBio's oral drug boosts growth in children with dwarfism in late-stage trial - Reuters
BioMarin Bet on Amicus To Ease Voxzogo’s Decline. Will It Work? - BioSpace
BridgeBio Nears 52-Week High On Strong Dwarfism Trial Data, Plans FDA Filing In 2026 - Bitget
Pharma companies left out of Trump's drug-pricing deals look for way in - marketscreener.com
Earnings Preview: BioMarin Pharmaceutical (BMRN) Q4 Earnings Expected to Decline - Finviz
Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? - Finviz
Biomarin receives Health Canada notice of compliance with conditions for Voxzogo, for achondroplasia - marketscreener.com
BioMarin Pharmaceutical (BMRN) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Acquisition plans to fuel BioMarin Pharmaceutical (BMRN), according to Barclays - MSN
What Does the Street Think About BioMarin Pharmaceutical Inc. (BMRN)? - Finviz
BioMarin Pharmaceutical Stock Outlook Looks Promising - Intellectia AI
BioMarin’s Strategic Acquisition Nears Critical Data Readout - AD HOC NEWS
Acquisition Plans to Fuel BioMarin Pharmaceutical (BMRN), According to Barclays - Finviz
A Look At BioMarin Pharmaceutical (BMRN) Valuation After Recent Share Price Momentum - Sahm
Assessing BioMarin Pharmaceutical: Insights From 5 Financial Analysts - Benzinga
BioMarin Pharmaceutical (NASDAQ:BMRN) Price Target Lowered to $84.00 at Piper Sandler - MarketBeat
The Best Biotech Stocks to Buy - Morningstar
The Top 12 Companies Hiring in Biopharma Now - BioSpace
Callan Family Office LLC Has $2.27 Million Holdings in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
Achondroplasia Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | BioMarin Pharmaceuticals, BridgeBio/ QED Therapeutics, Ribomic Inc, Sanofi - Barchart.com
AlphaQuest LLC Sells 21,696 Shares of BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Sues Zydus to Block Copy of Dwarfism Drug Voxzogo - Bloomberg Law News
BioMarin Pharmaceutical Inc. (BMRN): Investor Outlook on a Biotech Leader with 60% Upside Potential - DirectorsTalk Interviews
BioMarin lines up $850m bond sale to finance Amicus takeover - The Pharma Letter
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN
(BMRN) Movement as an Input in Quant Signal Sets - Stock Traders Daily
The Right Play On BioMarin Pharmaceuticals (NASDAQ:BMRN) - Seeking Alpha
BioMarin Pharmaceutical Inc. $BMRN Shares Purchased by Federated Hermes Inc. - MarketBeat
Investors Holding Back On BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) - 富途牛牛
Should You Buy BioMarin Pharmaceutical Before Feb. 18? - Finviz
BioMarin prices $850 million in senior notes to fund Amicus acquisition - Investing.com India
BioMarin Secures Major Debt Financing for Amicus Acquisition - TipRanks
BioMarin Pharmaceutical Inc Announces Pricing of Senior Notes and Loan Syndication - TradingView
BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility - Chartmill
Hussman Strategic Advisors Inc. Takes $1.14 Million Position in BioMarin Pharmaceutical Inc. $BMRN - MarketBeat
BioMarin Pharmaceutical Inc. $BMRN Shares Sold by Mitsubishi UFJ Trust & Banking Corp - MarketBeat
BioMarin Weighs Amicus Deal And Billions In New Debt Financing - simplywall.st
BioMarin Pharmaceutical (NASDAQ:BMRN) Now Covered by Barclays - MarketBeat
Upcoming Acquisition Resulting in Bullish Stance on BioMarin Pharmaceutical (BMRN) - Finviz
Assessing BioMarin Pharmaceutical (BMRN) Valuation As Investors Revisit The Rare Disease Specialist - Sahm
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):